CAPR Capricor Therapeutics Inc

Price (delayed)

$28.06

Market cap

$1.63B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.32

Enterprise value

$1.53B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 2

Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead ...

Highlights
CAPR's equity has soared by 118% year-on-year but it is down by 9% since the previous quarter
CAPR's quick ratio is up by 28% YoY but it is down by 7% QoQ
Capricor Therapeutics's net income has shrunk by 108% YoY and by 9% QoQ
CAPR's revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of CAPR

CAPR stock price

How has the Capricor Therapeutics stock price performed over time
Intraday
1.52%
1 week
-3.61%
1 month
-16.24%
1 year
127.39%
YTD
-2.77%
QTD
-7.7%

Financial performance

How have Capricor Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$119.93M
Net income
-$114.59M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 109% year-on-year and by 11% since the previous quarter
Capricor Therapeutics's net income has shrunk by 108% YoY and by 9% QoQ
CAPR's revenue has dropped by 100% year-on-year
Capricor Therapeutics's gross profit has shrunk by 100% YoY

Price vs fundamentals

How does CAPR's price correlate with its fundamentals

Growth

What is Capricor Therapeutics's growth rate over time

Valuation

What is Capricor Therapeutics stock price valuation
P/E
N/A
P/B
5.79
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 69% year-on-year and by 2.7% since the previous quarter
CAPR's equity has soared by 118% year-on-year but it is down by 9% since the previous quarter
CAPR's P/B is 33% lower than its 5-year quarterly average of 8.5 but 21% higher than its last 4 quarters average of 4.7
CAPR's revenue has dropped by 100% year-on-year

Efficiency

How efficient is Capricor Therapeutics business performance
CAPR's ROIC is down by 22% YoY but it is up by 16% from the previous quarter
The ROE has increased by 12% QoQ and by 5% YoY
The ROA has increased by 11% QoQ

Dividends

What is CAPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CAPR.

Financial health

How did Capricor Therapeutics financials performed over time
Capricor Therapeutics's total assets has surged by 112% YoY but it has decreased by 8% QoQ
The company's total liabilities has surged by 82% YoY but it fell by 5% QoQ
The debt is 95% smaller than the equity
CAPR's equity has soared by 118% year-on-year but it is down by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.